💊Kyowa Hakko Kirin News、Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review Designation of Burosumab’s Biologics License Application 20171010

FDA, JPN

💊Notice Regarding Implementation of New Drug Discovery Program “JOINUS” Using Drug Repositioning Compound Libraries by Astellas Pharma, Mitsubishi Tanabe Pharma and Daiichi Sankyo

JPN, Pharmaceutical

💊Kyowa Hakko Kirin Announces Discontinuation for Developing ARQ 197 (Tivantinib)

JPN, Pharmaceutical

💡ChromaJean to Launch at Takeda’s Shonan Research Center  2017年10月2日

💡ChromaJean to Launch

💡ChromaJean to Launch